ILUMYA® (tildrakizumab-asmn)
Moderate-to-Severe Plaque Psoriasis
Key Facts
About Sun Pharmaceutical
Sun Pharma's mission is to provide high-quality, affordable medicines globally, improving access and patient care. Its key achievement is transforming from a small startup in 1983 into a global pharmaceutical titan with a market cap exceeding $45 billion, largely through strategic acquisitions like Ranbaxy. The company's strategy is built on a dual engine: dominating the complex generics market while accelerating growth in high-margin specialty products and novel drug delivery systems across key therapeutic areas like dermatology, ophthalmology, and oncology.
View full company profileAbout Sun Pharmaceutical
Sun Pharma's mission is to provide high-quality, affordable medicines globally, improving access and patient care. Its key achievement is transforming from a small startup in 1983 into a global pharmaceutical titan with a market cap exceeding $45 billion, largely through strategic acquisitions like Ranbaxy. The company's strategy is built on a dual engine: dominating the complex generics market while accelerating growth in high-margin specialty products and novel drug delivery systems across key therapeutic areas like dermatology, ophthalmology, and oncology.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| ICOTYDE (icotrokinra) | Johnson and Johnson Innovative Medicine | Approved |
| Iruxolimab (AK101) | Akeso | Approved |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Approved |
| Envudeucitinib (ESK-001) | Alumis | Phase 3 |
| ORKA-001 | Oruka Therapeutics | Phase 1/2 |